Shukra Pharmaceuticals Ltd
Declaration of Financial Results for the quarter and year ended march 31, 2026
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 07 May 2026, 10:33 PM IST · BSE ID: d1028737-6a02-4004-9004-29976bd9e074
View Original BSE Filing (PDF)
⚡ Quick Answer
Shukra Pharmaceuticals Ltd reported audited financial results for FY26 on May 7, 2026, with a net profit of Rs. 2,196.88 Lakhs. The company also recommended a final dividend of Re. 0.01 per equity share and approved the allotment of 17,35,000 equity shares upon warrant conversion, raising Rs. 4,42,42,500. This increased the paid-up capital.
💡
In Simple Terms
The company reported its annual financial results, declared a small dividend, and converted some special shares into regular shares for promoters.
🤖 AI Summary
- Board approved Standalone Audited Financial Results for Q4 and FY ended March 31, 2026.
- Company reported a Net Profit after Tax of Rs. 2,196.88 Lakhs for the financial year 2025-26.
- Board recommended a final dividend of Re. 0.01 (1%) per equity share of Re. 1/- each for FY26.
- Approved allotment of 17,35,000 equity shares to promoters upon warrant conversion, raising Rs. 4,42,42,500.
- Paid-up equity capital increased from Rs. 43,78,79,440 to Rs. 43,96,14,440 post allotment.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Net Profit / (Loss) from Ordinary Activities after Tax (FY26)
Rs. 2,196.88 Lakhs
Net Profit / (Loss) from Ordinary Activities after Tax (Q4 FY26)
(Rs. 18.79) Lakhs
Dividend per equity share
Rs. 0.01
Proceeds from warrant conversion
Rs. 4,42,42,500
Equity shares allotted (warrant conversion)
17,35,000
Paid-up equity capital (post-allotment)
Rs. 43,96,14,440
Total outstanding warrants
29,08,000
🏢 How This Affects the Company
The company's paid-up equity capital increased by Rs. 17,35,000 from the warrant conversion, with a cash inflow of Rs. 4,42,42,500. The total equity increased from Rs. 6,283.59 Lakhs to Rs. 8,983.25 Lakhs as of March 31, 2026.
The conversion of warrants by promoters mitigates the risk of dilution at a lower price point if conversion was delayed, securing the capital infusion.
👥 What This Means For Shareholders
✅
Action Required
Shareholders must approve the recommended dividend at the upcoming Annual General Meeting.
👤
Who Is Affected
All shareholders of record on the to-be-announced record date will be eligible for the Rs. 0.01 per share dividend. Promoters Dakshesh Shah and Parshva Texchem India Private Limited now hold 17,35,000 additional equity shares.
🔍
Management Signal
Management is fulfilling its commitment to warrant conversion and returning a nominal dividend to shareholders, while also growing equity capital.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Annual General Meeting date — for dividend approval and other resolutions.
Dividend record date — for eligibility of the Rs. 0.01 per share payout.
Subsequent warrant conversions — track remaining 29,08,000 outstanding warrants.
MEDIUM RISK
The company reported a quarterly loss for Q4 FY26. Future warrant conversions could lead to further dilution.
💡 Investor Takeaway
Shukra Pharmaceuticals declared a Net Profit after Tax of Rs. 2,196.88 Lakhs for FY26, despite a Q4 FY26 loss of (Rs. 18.79) Lakhs. The board recommended a final dividend of Re. 0.01 per share and completed a Rs. 4,42,42,500 promoter warrant conversion, increasing paid-up capital to Rs. 43,96,14,440.
⚖️ Strengths & Concerns
✅ Positives
- Net Profit after Tax for FY26 stood at Rs. 2,196.88 Lakhs, indicating sustained profitability for the full financial year.
- Cash inflow of Rs. 4,42,42,500 from the conversion of 17,35,000 share warrants strengthens the company's financial position.
⚠️ Concerns
- Net Profit / (Loss) after Tax for Q4 FY26 was (Rs. 18.79) Lakhs, reporting a loss for the quarter.
- The recommended final dividend of Re. 0.01 per equity share is a minimal payout, representing 1% of face value.
📅 Company Track Record
Shukra Pharmaceuticals recently intimated no deviation in the utilization of funds from its Rs. 3,94,65,500 preferential issue, as of May 7, 2026. Prior to this, the company had reported a Q4 FY26 Standalone Net Profit of Rs. (18.79) Lakhs and a Rs. 0.01 dividend recommendation on May 7, 2026.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Shukra Pharmaceuticals' net profit for FY26?
Shukra Pharmaceuticals reported a net profit of Rs. 2,196.88 Lakhs for the financial year ended March 31, 2026.
What dividend did Shukra Pharmaceuticals recommend for FY26?
Shukra Pharmaceuticals' board recommended a final dividend of Re. 0.01 per equity share for the financial year ended March 31, 2026.
How much did Shukra Pharmaceuticals raise from warrant conversion in FY26?
Shukra Pharmaceuticals raised Rs. 4,42,42,500 by approving the allotment of 17,35,000 equity shares upon warrant conversion.
What was Shukra Pharmaceuticals' profit for Q4 FY26?
For the quarter ended March 31, 2026 (Q4 FY26), Shukra Pharmaceuticals reported a net profit of (Rs. 18.79) Lakhs.
Questions based on this BSE filing only. For information purposes.